CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer

被引：0
|
作者：
Alves, C. [1 ]
Elias, D. [1 ]
Lyng, M. [1 ]
Bak, M. [2 ]
Lykkesfeldt, A. [3 ]
Ditzel, H. [1 ]
机构：
[1] Univ Southern Denmark, Canc & Inflammat Res, Odense, Denmark
[2] Univ Southern Denmark, Pathol, Odense, Denmark
[3] Danish Canc Soc, Res Ctr, Breast Canc Grp Cell Death & Metab, Copenhagen, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61416-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [21] Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer
    Bayraktar, Soley
    Batoo, Sameer
    Al-Hattab, Eyad
    Basu, Sandeep
    Okuno, Scott
    Gluck, Stefan
    FUTURE ONCOLOGY, 2020, 16 (32) : 2661 - 2672
  • [22] CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
    de Melo Gagliato, Debora
    Buzaid, Antonio C.
    Manuel Perez-Garcia, Jose
    Llombart, Antonio
    Cortes, Javier
    CANCERS, 2020, 12 (09) : 1 - 19
  • [23] Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer
    Portman, Neil
    Milioli, Heloisa
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne
    Swarbrick, Alex
    Caldon, Liz
    Lim, Elgene
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
  • [25] Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR plus ) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
    Brett, Jamie O.
    Herman, Paige E.
    Mayer, Erica L.
    Bardia, Aditya
    Wander, Seth A.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 222 - 232
  • [26] Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors
    Lipton, N. J.
    Jesin, J.
    Warner, E.
    Cao, X.
    Kiss, A.
    Desautels, D.
    Jerzak, K. J.
    CURRENT ONCOLOGY, 2020, 27 (03) : 127 - 134
  • [27] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [28] Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer
    Peuker, C. A.
    Yaghobramzi, S.
    Grunert, C.
    Keilholz, L.
    Hennig, S.
    Schaper, S.
    Brucker, S.
    Decker, T.
    Fasching, P.
    Fehm, T.
    Janni, W.
    Kuemmel, S.
    Schneeweiss, A.
    Schuler, M.
    Lueftner, D.
    Busse, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 159 - 159
  • [29] Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer
    Witkiewicz, Agnieszka
    CANCER RESEARCH, 2023, 83 (05)
  • [30] Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    Watt, April C.
    Goel, Shom
    BREAST CANCER RESEARCH, 2022, 24 (01)
12345